Get the Stockscreener App
223.01
1.17%
2.58
After Hours:
222.49
-0.52
-0.23%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $223.01, with a volume of 6.58M.
It is up +1.17% in the last 24 hours and down -2.93% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$220.43
Open:
$220.51
24h Volume:
6.58M
Relative Volume:
1.08
Market Cap:
$394.14B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
168.27
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
+1.71%
1M Performance:
-2.93%
6M Performance:
+17.80%
1Y Performance:
+26.96%
1-Day Range:
$219.56
$224.02
1-Week Range:
$216.70
$226.86
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
223.01 | 389.58B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,037.15 | 916.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.25 | 547.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
NVS
Novartis Ag Adr
|
148.68 | 285.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.27 | 268.90B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie’s US$100b Drug Pricing Pact Reshapes Growth And Policy Outlook - Yahoo Finance UK
AbbVie stock rises into weekend as Feb. 4 earnings loom — what traders watch next - TechStock²
AbbVie Inc. $ABBV Shares Sold by Transcend Capital Advisors LLC - MarketBeat
Thrivent Financial for Lutherans Acquires 34,384 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Atle Fund Management AB - MarketBeat
Principal Financial Group Inc. Buys 220,950 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie stock (ABBV) firms up into earnings week as markets turn cautious - TechStock²
AbbVie Inc. (ABBV) Balances Analyst Caution with Pipeline Progress and Long-Term Growth - Finviz
Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma - Finviz
Lingohr Asset Management GmbH Acquires 23,058 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Stake Decreased by Keybank National Association OH - MarketBeat
National Pension Service Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
Better Long-Term Buy: This Emerging Player or the Industry Leader? - Finviz
Better Long-Term Buy: This Emerging Player or the Industry Leader? - The Motley Fool
AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus - TechStock²
Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
AbbVie Stock: Analyst Estimates & Ratings - Yahoo Finance
Townsquare Capital LLC Sells 7,540 Shares of AbbVie Inc. $ABBV - MarketBeat
Alpha Cubed Investments LLC Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
Spinal Cord Injury Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Kringle Pharma, Neuroplast, AbbVie, and Mitsubishi Tanabe Pharma America - Barchart.com
AbbVie Launches Love in Mind to Spotlight the Emotional Impact of Migraine on Romantic Relationships - Investing News Network
3 in 4 with migraine say attacks hurt their romantic lives - Stock Titan
Great Lakes Advisors LLC Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
TD Waterhouse Canada Inc. Has $26.55 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Traynor Capital Management Inc. Acquires 13,555 Shares of AbbVie Inc. $ABBV - MarketBeat
AustralianSuper Pty Ltd Has $49.93 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AE Wealth Management LLC Acquires 18,651 Shares of AbbVie Inc. $ABBV - MarketBeat
Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
AbbVie (ABBV) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Why AbbVie Stock Trounced the Market in 2025 - Finviz
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call - Finimize
AbbVie (NYSE:ABBV) Stock Price Down 2.2% on Analyst Downgrade - MarketBeat
Taking The First Steps Towards Digitalizing Biopharma Development - Bioprocess Online
UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs - Benzinga
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
AbbVie's Irish operations in firing line as Trump targets Botox prices - Irish Examiner
AbbVie Inc. $ABBV Shares Bought by Mirae Asset Global Investments Co. Ltd. - MarketBeat
AbbVie Partners with Trump Administration to Enhance Access and Affordability - Intellectia AI
Truist Financial Corp Has $533.94 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades' - Benzinga
AbbVie Inc. $ABBV Shares Bought by Federated Hermes Inc. - MarketBeat
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle - Benzinga
CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks - TipRanks
Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)? - Yahoo Finance
US names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - wkzo.com
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - Yahoo! Finance Canada
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks - Investing.com Canada
AbbVie stock rises as insurers crater and the Fed week kicks off - TechStock²
Citigroup Issues Pessimistic Forecast for AbbVie (NYSE:ABBV) Stock Price - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):